CO6420392A2 - Un metodo de tratamiento de un transtorno neurologico - Google Patents

Un metodo de tratamiento de un transtorno neurologico

Info

Publication number
CO6420392A2
CO6420392A2 CO12018250A CO12018250A CO6420392A2 CO 6420392 A2 CO6420392 A2 CO 6420392A2 CO 12018250 A CO12018250 A CO 12018250A CO 12018250 A CO12018250 A CO 12018250A CO 6420392 A2 CO6420392 A2 CO 6420392A2
Authority
CO
Colombia
Prior art keywords
treatment method
neurological disorder
pramipexole
parkinson
administration
Prior art date
Application number
CO12018250A
Other languages
English (en)
Inventor
Michael L Vieira
Jones Woodrow Bryan Jr
Original Assignee
Supernus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Supernus Pharmaceuticals Inc filed Critical Supernus Pharmaceuticals Inc
Publication of CO6420392A2 publication Critical patent/CO6420392A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describe un método para tratar padecimientos neurológicos, tales como enfermedad de Parkinson y Síndrome de Piernas Inquietas, en un sujeto mamífero. El método comprende la administración de una formulación de liberación controlada una vez al día de pramipexol, cuya formulación proporciona un perfil de PK que asciende consistentemente durante las horas de sueño.
CO12018250A 2009-07-02 2012-02-02 Un metodo de tratamiento de un transtorno neurologico CO6420392A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22268409P 2009-07-02 2009-07-02

Publications (1)

Publication Number Publication Date
CO6420392A2 true CO6420392A2 (es) 2012-04-16

Family

ID=43411429

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12018250A CO6420392A2 (es) 2009-07-02 2012-02-02 Un metodo de tratamiento de un transtorno neurologico

Country Status (9)

Country Link
US (1) US20110003870A1 (es)
EP (1) EP2448411A4 (es)
JP (1) JP2012532138A (es)
AU (1) AU2010266285A1 (es)
BR (1) BRPI1010129A2 (es)
CA (1) CA2767029A1 (es)
CO (1) CO6420392A2 (es)
MX (1) MX2012000096A (es)
WO (1) WO2011002891A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102670550A (zh) * 2011-03-14 2012-09-19 北京天衡药物研究院 盐酸普拉克索渗透泵型控释片
EP3310344A1 (en) 2015-06-19 2018-04-25 Biotie Therapies, Inc. Controlled-release tozadenant formulations

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4281A (en) * 1845-11-21 Alexandee andeeson
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US8329217B2 (en) * 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
US20050226926A1 (en) * 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
AR040682A1 (es) * 2002-07-25 2005-04-13 Pharmacia Corp Forma de dosificacion una vez al dia de pramipexol
US20050119249A1 (en) * 2003-12-02 2005-06-02 Erik Buntinx Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
CN101849921A (zh) * 2004-08-13 2010-10-06 贝林格尔·英格海姆国际有限公司 包含普拉克索或其可药用盐的延长释放片剂
ES2536460T3 (es) * 2004-09-21 2015-05-25 Shandong Luye Pharmaceutical Co., Ltd. Formulación de acción prolongada y liberación controlada que contiene un agonista de receptores de dopamina y método de preparación de la misma
WO2006046256A1 (en) * 2004-10-27 2006-05-04 Alembic Limited Extended release formulation of pramipexole dihydrochloride
CA2613107A1 (en) * 2005-06-23 2007-01-04 Spherics, Inc. Delayed release or extended-delayed release dosage forms of pramipexole
DE102005031577A1 (de) * 2005-07-06 2007-01-11 Bayer Healthcare Ag Pharmazeutische Darreichungsformen enthaltend eine Wirkstoffkombination von Nifedipin und/oder Nisoldipin und einem Angiotensin-II Antagonisten
US20070134315A1 (en) * 2005-12-08 2007-06-14 Viera Michael L Orally administrable extended release pellet and tablet formulations of a highly water soluble compound
WO2007090882A2 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Pharmaceutical extended release compositions comprising pramipexole
US8524695B2 (en) * 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
US20090004281A1 (en) * 2007-06-26 2009-01-01 Biovail Laboratories International S.R.L. Multiparticulate osmotic delivery system
WO2009152041A2 (en) * 2008-06-09 2009-12-17 Supernus Pharmaceuticals, Inc. Controlled release formulations of pramipexole

Also Published As

Publication number Publication date
EP2448411A4 (en) 2012-11-28
JP2012532138A (ja) 2012-12-13
BRPI1010129A2 (pt) 2017-01-31
EP2448411A1 (en) 2012-05-09
CA2767029A1 (en) 2011-01-06
MX2012000096A (es) 2012-04-02
AU2010266285A1 (en) 2012-02-09
US20110003870A1 (en) 2011-01-06
WO2011002891A1 (en) 2011-01-06

Similar Documents

Publication Publication Date Title
SMT201300095B (it) Uso dell'estere etilico dell'acido eicosapentaenoico per trattare l'ipertrigliceridemia
GB2491327A (en) Delayed prolonged drug delivery
CY1124135T1 (el) Δοσολογικα σχηματα για την αγωγη της νοσου ρομρε
PE20151375A1 (es) Compuestos ciclicos eter pirazol-4-il-heterociclil-carboxamida y metodos de utilizacion
EA033067B1 (ru) Способ лечения метаболических расстройств у пациента, имеющего противопоказание к назначению бигуанидного соединения
NZ702093A (en) Methods of lowering proprotein convertase subtilisin/kexin type 9 (pcsk9)
ECSP13012611A (es) Derivados de pirazol-aminopirimidina como moduladores de la lrrk2
MX2013011726A (es) Metodo de tratamiento o mejoramiento de transtornos metabolicos usando el factor de diferenciacion de crecimiento 15 (gdf-15).
NZ598085A (en) Methods, compounds, and compositions for delivering 1,3-propanedisulfonic acid
CO6630133A2 (es) Compuestos de pirazol -4-il heterociclil -carboxamida y métodos de uso
BR112015029972A2 (pt) composto, composição farmacêutica, processo para a preparação de uma composição farmacêutica, método para o tratamento de uma doença, conjunto e utilização de um composto
WO2011085216A3 (en) Use of faah inhibitors for treating parkinson's disease and restless legs syndrome
MY165003A (en) Compositions of rotigotine, derivatives thereof, or pharmaceutically acceptable salts of rotigotine or its derivative
NZ596672A (en) Use of pde7 inhibitors for the treatment of movement disorders
CL2012002540A1 (es) Hidrato de hidrocloruro de agomelatina; forma cristalina; metodo de preparacion; composicion farmaceutica ; y su uso para el tratamiento de trastornos del sueño, estrés, ansiedad, depresion mayor, enfermedades cardiovasculares, entre otras.
GEP20196969B (en) New therapeutical composition containing apomorphine as active ingredient
CO6561789A2 (es) Método de tratamiento
MX2013008715A (es) Uso de (s) -esmolol para controlar la irritacion venosa asociada con el tratamiento de un padecimiento cardiaco.
PH12018550212A1 (en) Rotigotine behenate and preparation method and use thereof
CO6420392A2 (es) Un metodo de tratamiento de un transtorno neurologico
BR112013026644A2 (pt) método para a modulação da atividade de citocina
MX2022002306A (es) Metodos de tratamiento de enfermedades oculares con un implante para la administracion sostenida de farmacos.
DOP2012000056A (es) Agente terapeutico para trastornos de ansiedad
EP2703006A4 (en) USE OF A CALCINEURIN 1 REGULATOR FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF DISEASES ASSOCIATED WITH ENHANCED NF-KB ACTIVITY
UA62637U (ru) Способ лечения вегетативных и тревожных расстройств у больных с синдромом вегетативной дистонии

Legal Events

Date Code Title Description
FC Application refused